WE CLAIM:

1. Use of a histamine-3 receptor inverse agonist, in the manufacture of a medicament for the treatment of narcolepsy, excessive daytime sleepiness, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder in a patient, wherein the histamine-3 receptor inverse agonist is a compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

2. Use of histamine-3 receptor inverse agonist as claimed in claim 1, wherein pharmaceutically acceptable salts of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide are selected from hydrochloride salt, oxalate salt, succinate salt and tartrate salt.

3. Use of histamine-3 receptor inverse agonist as claimed in claim 1 or 2, wherein the pharmaceutically acceptable salt of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

4. Use of histamine-3 receptor inverse agonist as claimed in claim 1, in the manufacture of a medicament for the treatment of narcolepsy, wherein the histamine-3 receptor inverse agonist is a compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

5. Use of histamine-3 receptor inverse agonist as claimed in claim 4, in the manufacture of a medicament for the treatment of narcolepsy, wherein the pharmaceutically acceptable salt of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

6. Use of histamine-3 receptor inverse agonist as claimed in any one of claims 1 to 5, wherein narcolepsy is narcolepsy associated with cataplexy.

7. Use of histamine-3 receptor inverse agonist as claimed in any one of claims 1 to 5, wherein narcolepsy is narcolepsy not associated with cataplexy.

8. Use of histamine-3 receptor inverse agonist as claimed in any one of claims 1 to 5, wherein narcolepsy is narcolepsy due to medical condition.

9. Use of a histamine-3 receptor inverse agonist as claimed in any one of claims 1 to 3 in the manufacture of a medicament for the treatment of excessive daytime sleepiness.

10. Use of a histamine-3 receptor inverse agonist as claimed in claim 9, wherein the medicament is for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, restless leg syndrome, REM behavior disorder, posttraumatic stress disorder, autism, Down syndrome**,** periodic limb movements in sleep, menstrual-related hypersomnia or Kleine-Levin syndrome.

11. Use of a histamine-3 receptor inverse agonist as claimed in any one of the claims 1 to 3, wherein the medicament is for the treatment of circadian rhythm sleep disorders.

12. Use of a histamine-3 receptor inverse agonist as claimed in claim 11, wherein circadian rhythm sleep disorder is selected from irregular sleep-wake type, jet lag type or shift work type.

13. Use of a histamine-3 receptor inverse agonist as claimed in any one of the claims 1 to 3, wherein the medicament is for the treatment of sleep and vigilance disorders associated with Parkinson’s disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder.

14. Use of the histamine-3 receptor inverse agonist as claimed in claim 13, wherein the dementia is selected from Lewy body dementia, senile dementia, vascular dementia, dementia due to Alzheimer’s disease, dementia due to Parkinson’s disease and/or Frontotemporal dementia.

15. Use of a pharmaceutical composition comprising a histamine-3 receptor inverse agonist and pharmaceutically acceptable excipients, wherein the histamine-3 receptor inverse agonist is N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the

treatment of narcolepsy, excessive daytime sleepiness, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder.

16. The use as claimed in claim 15, wherein the medicament is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

17. The use as claimed in claim 15 or 16, wherein the medicament is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.